New and potential clinical applications of KRAS as a cancer biomarker

Bibliography

• Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9
   PubMed Web of Science ®Google Scholar
• Bamford S, Dawson E, Forbes S, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;91:355-58
   PubMed Web of Science ®Google Scholar
• Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593-611
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
   PubMed Web of Science ®Google Scholar
• Vidic S, Markelc B, Sersa G, MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo. Cancer Gene Ther 2010;17:409-19
   PubMed Web of Science ®Google Scholar
• Sakuma T, Kijima H, Nishi M, An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer. Tokai J Exp Clin Med 2004;29:35-42
   PubMedGoogle Scholar
• Cogoi S, Codognotto A, Rapozzi V, Transcription inhibition of oncogenic KRAS by a mutation-selective peptide nucleic acid conjugated to the PKKKRKV nuclear localization signal peptide. Biochemistry 2005;44:10510-19
   PubMed Web of Science ®Google Scholar
• Carbone DP, Ciernik IF, Kelley MJ, Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 2005;23:5099-107
   PubMed Web of Science ®Google Scholar
• Lu Y, Bellgrau D, Dwyer-Nield LD, Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 2004;64:5084-8
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of the therapeutic vaccine GI-4000 in combination with gemcitabine versus placebo for the treatment of non-metastatic, post-resection pancreas cancer. Available from: http://www.clinicaltrials.gov/ct2/results?term=00300950 [Last accessed 17 April 2010]
   Google Scholar
• van Krieken JH, Jung A, Kirchner T, KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008;453:417-31
   PubMed Web of Science ®Google Scholar
• Artale S, Sartore-Bianchi A, Veronese SM, Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:4217-19
   PubMed Web of Science ®Google Scholar
• Oliveira C, Velho S, Moutinho C, KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007;26:158-63
   PubMed Web of Science ®Google Scholar
• Italiano A, Hostein I, Soubeyran I, KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 2010;17:1429-34
   PubMed Web of Science ®Google Scholar
• Molinari F, Martin V, Saletti P, Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 2009;100:1087-94
   PubMed Web of Science ®Google Scholar
• Do H, Krypuy M, Mitchell PL, High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142-56
   PubMed Web of Science ®Google Scholar
• Lilleberg SL, Durocher J, Sanders C, High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. Ann NY Acad Sci 2004;1022:250-6
   PubMed Web of Science ®Google Scholar
• Lleonart ME, Ramon y Cajal S, Groopman JD, Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis. Nucleic Acids Res 2004;32:e53-60
   PubMed Web of Science ®Google Scholar
• Bjorheim J, Lystad S, Lindblom A, Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction. Mutat Res 1998;403:103-12
   PubMed Web of Science ®Google Scholar
• Keohavong P, Zhu D, Whiteside TL, Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. Anal Biochem 1997;247:394-403
   PubMed Web of Science ®Google Scholar
• Hardingham JE, Kotasek D, Farmer B, Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res 1993;53:3455-8
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Orita M, Shiraishi M, Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990;5:1037-43
   PubMed Web of Science ®Google Scholar
• Kotoula V, Charalambous E, Biesmans B, Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One 2009;4:e7746
   PubMedGoogle Scholar
• Ogino S, Kawasaki T, Brahmandam M, Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-21
   PubMed Web of Science ®Google Scholar
• Tol J, Dijkstra JR, Vink-Borger ME, High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 2009: published online 13 March 2009, doi: 10.1111/j.1582-4934.2009.00788
   Web of Science ®Google Scholar
• Keohavong P, DeMichele MA, Melacrinos AC, Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 1996;2:411-18
   PubMed Web of Science ®Google Scholar
• Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 2008;9:676-82
   PubMed Web of Science ®Google Scholar
• Sasaki H, Okuda K, Kawano O, Nras and Kras mutation in Japanese lung cancer patients: genotyping analysis using LightCycler. Oncol Rep 2007;18:623-8
   PubMed Web of Science ®Google Scholar
• Gandara DR, Lara PN, Lau DH, Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach. Lung Cancer 2001;34(Suppl 3):S75-80
   PubMedGoogle Scholar
• Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 1999;20:1507-10
   PubMed Web of Science ®Google Scholar
• Keohavong P, Mady HH, Gao WM, Topographic analysis of K-ras mutations in histologically normal lung tissues and tumours of lung cancer patients. Br J Cancer 2001;85:235-41
   PubMed Web of Science ®Google Scholar
• Tsai CM, Chang KT, Perng RP, Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993;85:897-901
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, Boerrigter L, Top B, Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 1997;15:285-91
   PubMed Web of Science ®Google Scholar
• Schiller JH, Adak S, Feins RH, Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 2001;19:448-57
   PubMed Web of Science ®Google Scholar
• Tsao MS, Aviel-Ronen S, Ding K, Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5240-7
   PubMed Web of Science ®Google Scholar
• Eberhard DA, Johnson BE, Amler LC, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9
   PubMed Web of Science ®Google Scholar
• Rusch V, Baselga J, Cordon-Cardo C, Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993;53:2379-85
   PubMed Web of Science ®Google Scholar
• Bonomi PD, Buckingham L, Coon J. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 2007;13:s4606-12
   PubMed Web of Science ®Google Scholar
• Uchida A, Hirano S, Kitao H, Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci 2007;98:357-63
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55
   PubMed Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17
   PubMed Web of Science ®Google Scholar
• Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6:201-5
   PubMedGoogle Scholar
• Zhu CQ, da Cunha Santos G, Ding K, Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-75
   PubMed Web of Science ®Google Scholar
• Miller VA, Riely GJ, Zakowski MF, Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008;26:1472-8
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA Jr, Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-42
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Cappuzzo F, Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007;18:752-60
   PubMed Web of Science ®Google Scholar
• Marchetti A, Milella M, Felicioni L, Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009;11:1084-92
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst RS, Manegold C, Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol 2004;22:777-84
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JH, Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785-94
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R, TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A, Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-52
   PubMed Web of Science ®Google Scholar
• Lin H, Jiang J, Liang X, Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010: published online 9 February 2010, doi:10.1016/j.lungcan.2010.01.009
   Google Scholar
• Ausch C, Buxhofer-Ausch V, Oberkanins C, Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn 2009;11:508-13
   PubMed Web of Science ®Google Scholar
• Andreyev HJ, Norman AR, Cunningham D, Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 2001;85:692-6
   PubMed Web of Science ®Google Scholar
• Wang JY, Wang YH, Jao SW, Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. Oncol Rep 2006;16:1245-52
   PubMed Web of Science ®Google Scholar
• Catalogue of somatic mutations in cancer. Available from: http://www.sanger.ac.uk/search?db=cosmic&t=KRAS [Last accessed 22 March 2010]
   Google Scholar
• Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005;6:322-7
   PubMed Web of Science ®Google Scholar
• Toyooka S, Tsukuda K, Ouchida M, Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. Oncol Rep 2003;10:1455-9
   PubMed Web of Science ®Google Scholar
• Edkins S, O'Meara S, Parker A, Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006;5:928-32
   PubMed Web of Science ®Google Scholar
• Russo A, Bazan V, Agnese V, Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 2005;16(Suppl 4):iv44-9
   PubMedGoogle Scholar
• Oliveira C, Westra JL, Arango D, Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004;13:2303-11
   PubMed Web of Science ®Google Scholar
• Etienne-Grimaldi MC, Formento JL, Francoual M, K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008;14:4830-5
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Le Corre D, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5
   PubMed Web of Science ®Google Scholar
• Zlobec I, Bihl MP, Schwarb H, Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer;127:367-80
   PubMed Web of Science ®Google Scholar
• Cejas P, Lopez-Gomez M, Aguayo C, KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009;4:e8199
   PubMed Web of Science ®Google Scholar
• Houghton JA, Ebanks R, Harwood FG, Tillman DM. Inhibition of apoptosis after thymineless stress is conferred by oncogenic K-Ras in colon carcinoma cells. Clin Cancer Res 1998;4:2841-8
   PubMed Web of Science ®Google Scholar
• Scanlon KJ, Jiao L, Funato T, Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 1991;88:10591-5
   PubMed Web of Science ®Google Scholar
• Giovanella BC, Stehlin JS, Wall ME, DNA topoisomerase I – targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046-8
   PubMed Web of Science ®Google Scholar
• Ahnen DJ, Feigl P, Quan G, Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998;58:1149-58
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Cox J, Meyer W, Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU). Am J Clin Oncol 1997;20:527-9
   PubMed Web of Science ®Google Scholar
• Gnanasampanthan G, Elsaleh H, McCaul K, Iacopetta B. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer. J Pathol 2001;195:543-8
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
   PubMed Web of Science ®Google Scholar
• Loriot Y, Mordant P, Deutsch E, Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 2009;6:528-34
   PubMed Web of Science ®Google Scholar
• Spano JP, Lagorce C, Atlan D, Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005;16:102-8
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232
   PubMed Web of Science ®Google Scholar
• Spindler KL, Lindebjerg J, Nielsen JN, Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods. Int J Oncol 2006;29:1159-65
   PubMed Web of Science ®Google Scholar
• Ogino S, Meyerhardt JA, Cantor M, Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005;11:6650-6
   PubMed Web of Science ®Google Scholar
• Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304
   PubMedGoogle Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-19
   PubMed Web of Science ®Google Scholar
• Berlin J, Posey J, Tchekmedyian S, Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007;6:427-32
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Siena S, Humblet Y, An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008;19:92-8
   PubMed Web of Science ®Google Scholar
• Hecht JR, Patnaik A, Berlin J, Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007;110:980-8
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Marshall JL. Vascular endothelial growth factor plus epidermal growth factor receptor dual targeted therapy in metastatic colorectal cancer: synergy or antagonism? J Oncol 2009; doi:10.1155/2009/937305
   PubMedGoogle Scholar
• Van Cutsem E, Peeters M, Siena S, Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64
   PubMed Web of Science ®Google Scholar
• Adams R, Maughan T. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Rev Anticancer Ther 2007;7:503-18
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Finocchiaro G, Rossi E, EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008;19:717-23
   PubMed Web of Science ®Google Scholar
• Frattini M, Saletti P, Romagnani E, PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007;97:1139-45
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Moroni M, Veronese S, Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25:3238-45
   PubMed Web of Science ®Google Scholar
• Italiano A, Follana P, Caroli FX, Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008;15:649-54
   PubMed Web of Science ®Google Scholar
• Martin V, Mazzucchelli L, Frattini M. An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J Clin Pathol 2009;62:314-24
   PubMed Web of Science ®Google Scholar
• Moroni M, Sartore-Bianchi A, Veronese S, Siena S. EGFR FISH in colorectal cancer: what is the current reality? Lancet Oncol 2008;9:402-3
   PubMed Web of Science ®Google Scholar
• Personeni N, Fieuws S, Piessevaux H, Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008;14:5869-76
   PubMed Web of Science ®Google Scholar
• De Roock W, Piessevaux H, De Schutter J, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Boige V, KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9
   PubMed Web of Science ®Google Scholar
• Koliopanos A, Avgerinos C, Paraskeva C, Molecular aspects of carcinogenesis in pancreatic cancer. Hepatobiliary Pancreat Dis Int 2008;7:345-56
   PubMed Web of Science ®Google Scholar
• Nelson NJ. Pancreatic cancer research matures. J Natl Cancer Inst 2007;99:1432-4
   PubMed Web of Science ®Google Scholar
• Chu TM. Molecular diagnosis of pancreas carcinoma. J Clin Lab Anal 1997;11:225-31
   PubMed Web of Science ®Google Scholar
• Kawesha A, Ghaneh P, Andren-Sandberg A, K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21 WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000;89:469-74
   PubMed Web of Science ®Google Scholar
• Salek C, Minarikova P, Benesova L, Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer. Anticancer Res 2009;29:1803-10
   PubMed Web of Science ®Google Scholar
• Dergham ST, Dugan MC, Sarkar FH, Molecular alterations associated with improved survival in pancreatic cancer patients treated with radiation or chemotherapy. J Hepatobiliary Pancreat Surg 1998;5:269-72
   PubMedGoogle Scholar
• Shi C, Fukushima N, Abe T, Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther 2008;7:353-60
   PubMed Web of Science ®Google Scholar
• Tsiambas E, Karameris A, Lazaris AC, EGFR alterations in pancreatic ductal adenocarcinoma: a chromogenic in situ hybridization analysis based on tissue microarrays. Hepatogastroenterology 2006;53:452-7
   PubMed Web of Science ®Google Scholar
• Ueda S, Ogata S, Tsuda H, The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004;29:e1-8
   PubMed Web of Science ®Google Scholar
• Chang BW, Saif MW. Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap? Jop 2009;10:231-6
   PubMedGoogle Scholar
• Moore MJ, Goldstein D, Hamm J, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
   PubMed Web of Science ®Google Scholar
• Mayr D, Hirschmann A, Lohrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006;103:883-7
   PubMed Web of Science ®Google Scholar
• Enomoto T, Weghorst CM, Inoue M, K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991;139:777-85
   PubMed Web of Science ®Google Scholar
• Auner V, Kriegshauser G, Tong D, KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 2009;9:111-19
   PubMedGoogle Scholar
• Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003;202:97-9
   PubMed Web of Science ®Google Scholar
• Nakayama N, Nakayama K, Yeasmin S, KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer 2008;99:2020-8
   PubMed Web of Science ®Google Scholar
• Siwak DR, Carey M, Hennessy BT, Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010; doi:10.1155/2010/568938
   PubMedGoogle Scholar
• Secord AA, Blessing JA, Armstrong DK, Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 2008;108:493-9
   PubMed Web of Science ®Google Scholar
• Konner J, Schilder RJ, DeRosa FA, A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol 2008;110:140-5
   PubMed Web of Science ®Google Scholar
• Wagner U, du Bois A, Pfisterer J, Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy – a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 2007;105:132-7
   PubMed Web of Science ®Google Scholar
• Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41
   PubMed Web of Science ®Google Scholar
• Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009;16:8-13
   PubMed Web of Science ®Google Scholar
• Bergman L, Beelen ML, Gallee MP, Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000;356:881-7
   PubMed Web of Science ®Google Scholar
• Bernstein L, Deapen D, Cerhan JR, Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91:1654-62
   PubMed Web of Science ®Google Scholar
• Hachisuga T, Tsujioka H, Horiuchi S, K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene. Br J Cancer 2005;92:1098-103
   PubMed Web of Science ®Google Scholar
• Wallen M, Tomas E, Visakorpi T, Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. Cancer Chemother Pharmacol 2005;55:343-6
   PubMed Web of Science ®Google Scholar
• Turbiner J, Moreno-Bueno G, Dahiya S, Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. Mod Pathol 2008;21:925-36
   PubMed Web of Science ®Google Scholar
• Oza AM, Eisenhauer EA, Elit L, Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008;26:4319-25
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009;4:e7287
   PubMed Web of Science ®Google Scholar
• Bibeau F, Lopez-Crapez E, Di Fiore F, Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-9
   PubMed Web of Science ®Google Scholar